US Patent

US12115254 — Methods of use of emulsion formulations of an NK-1 receptor antagonist

Formulation · Assigned to Heron Therapeutics LLC · Expires 2035-09-18 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel pharmaceutical formulations of an NK-1 receptor antagonist suitable for parenteral administration, including intravenous administration.

USPTO Abstract

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Drugs covered by this patent

Patent Metadata

Patent number
US12115254
Jurisdiction
US
Classification
Formulation
Expires
2035-09-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Heron Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.